Improving Incidental Lung Nodule Follow-up, with Javier Zulueta, MD
Zulueta discussed Mount Sinai’s incidental lung nodule program using AI tools to improve follow-up and recent findings from the program presented at ATS.
Related Articles
Understanding Topical Steroid Withdrawal Versus Atopic Dermatitis, with Brad Glick, MD
In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.
Phase 3 Deucravacitinib Trial Meets ACR20 End Point in PsA
At week 16, investigators also observed nominally significant improvements in ACR50, ACR70, FACIT-Fatigue score, DAS28-CRP score, and dactylitis resolution pooled analysis.
Liver Lineup: Advances in MASH, PSC, and PBC Care at EASL 2025
In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.
Atopic Dermatitis Burden Among Families of Children Under 6 Years, with Amy S. Paller, MD
In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.
Kidney Compass: ERA 2025 Recap
A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.
Masked Taper + CBT-I Helps Patients Rethink Sleep Med Needs, with Constance Fung, MD
At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.
Predicting Cardiovascular Disease in Patients Without Risk Factors with Matthew Budoff, MD
Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.
Masked Taper + CBT-I Boosts Benzodiazepine Discontinuation, with Constance Fung, MD
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Anemia
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Latest Pharmacotherapy Developments for Sleep Apnea, with Danny Eckert, PhD
At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.